GB201616439D0 - Compounds and uses - Google Patents

Compounds and uses

Info

Publication number
GB201616439D0
GB201616439D0 GBGB1616439.4A GB201616439A GB201616439D0 GB 201616439 D0 GB201616439 D0 GB 201616439D0 GB 201616439 A GB201616439 A GB 201616439A GB 201616439 D0 GB201616439 D0 GB 201616439D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1616439.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MIRONID Ltd
Original Assignee
MIRONID Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MIRONID Ltd filed Critical MIRONID Ltd
Priority to GBGB1616439.4A priority Critical patent/GB201616439D0/en
Publication of GB201616439D0 publication Critical patent/GB201616439D0/en
Priority to JP2019515286A priority patent/JP7062643B2/ja
Priority to US16/337,344 priority patent/US11046660B2/en
Priority to PCT/GB2017/052898 priority patent/WO2018060704A1/en
Priority to EP17780158.6A priority patent/EP3519403B1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB1616439.4A 2016-09-28 2016-09-28 Compounds and uses Ceased GB201616439D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB1616439.4A GB201616439D0 (en) 2016-09-28 2016-09-28 Compounds and uses
JP2019515286A JP7062643B2 (ja) 2016-09-28 2017-09-28 化合物およびｐｄｅ４活性剤としてのそれらの使用
US16/337,344 US11046660B2 (en) 2016-09-28 2017-09-28 Compounds and their use as PDE4 activators
PCT/GB2017/052898 WO2018060704A1 (en) 2016-09-28 2017-09-28 Compounds and their use as pde4 activators
EP17780158.6A EP3519403B1 (en) 2016-09-28 2017-09-28 Compounds and their use as pde4 activators

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1616439.4A GB201616439D0 (en) 2016-09-28 2016-09-28 Compounds and uses

Publications (1)

Publication Number Publication Date
GB201616439D0 true GB201616439D0 (en) 2016-11-09

Family

ID=57539742

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1616439.4A Ceased GB201616439D0 (en) 2016-09-28 2016-09-28 Compounds and uses

Country Status (5)

Country Link
US (1) US11046660B2 (enExample)
EP (1) EP3519403B1 (enExample)
JP (1) JP7062643B2 (enExample)
GB (1) GB201616439D0 (enExample)
WO (1) WO2018060704A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201504763D0 (en) 2015-03-20 2015-05-06 Mironid Ltd Compounds and uses
GB201616439D0 (en) 2016-09-28 2016-11-09 Mironid Limited Compounds and uses
GB201805527D0 (en) 2018-04-04 2018-05-16 Mironid Ltd Compounds and their use as pde4 activators
GB202102088D0 (en) 2021-02-15 2021-03-31 Mironid Ltd Compounds and their use as pde4 activators
GB202211999D0 (en) 2022-08-17 2022-09-28 Mironid Ltd Compounds and their use as PDE4 activators
GB202212000D0 (en) 2022-08-17 2022-09-28 Mironid Ltd Compounds and their use as PDE4 activators
WO2025157695A1 (en) 2024-01-24 2025-07-31 Syngenta Crop Protection Ag Herbicidal pyrazole and triazole compounds

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ178996A (en) * 1974-11-15 1978-06-02 Kornis G Pyrfazole amides and thioamides;herbicidal compositions
JP3890453B2 (ja) 1996-09-18 2007-03-07 リードケミカル株式会社 新規２，４−ジオキソピロリジンおよび２，４−ジオキソテトラヒドロフラン誘導体及び該化合物を有効成分とする医薬
AU2004210711B2 (en) 2003-02-12 2010-07-08 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
CN1809559B (zh) * 2003-04-18 2010-06-02 记忆药物公司 作为磷酸二酯酶4抑制剂的吡唑衍生物
US7056932B2 (en) * 2003-12-19 2006-06-06 Hoffman-La Roche Inc. Heterocyclyl substituted 1-alkoxy acetic acid amides
US20070191711A1 (en) 2006-02-15 2007-08-16 Misonix, Incorporated Liquid processing and handling apparatus and associated method for use in medical procedures
EP2013176A2 (en) * 2006-02-27 2009-01-14 Sterix Limited Diaryl compounds as non-steroidal inhibitors of 17-beta hydroxysteroid dehydrogenase and/or steroid sulphatase for the treatment of oestrogen-related diseases such as hormone dependent breast cancer
EP2057152A1 (de) 2006-08-07 2009-05-13 Boehringer Ingelheim International GmbH Enantiomerenreine betaagonisten, verfahren zu deren herstellung und deren verwendung als arzneimittel
US20090264471A1 (en) 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazole Derivatives
US20100144733A1 (en) 2008-04-28 2010-06-10 Institute For Oneworld Health Compounds, compositions and methods comprising heteroaromatic derivatives
WO2010059838A2 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects
DE102009013642A1 (de) * 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylalaninderivate und deren Verwendung
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
JP2012526544A (ja) 2009-05-12 2012-11-01 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７
BRPI1007093A2 (pt) 2009-05-12 2017-06-06 Koninl Philips Electronics Nv fosfodiesterase 4d7 uso de pde4d7; composição metodo, metodo de aquisição de dados imunoensaio para detectar diagnosticar, monitorar ou prognosticar cancer de prostata ou para diagnosticar, detectar monitorar ou prognosticar progressao do cancer
US9408831B2 (en) 2010-04-07 2016-08-09 Celgene Corporation Methods for treating respiratory viral infection
CN103857661B (zh) 2011-08-11 2016-11-16 拜耳知识产权有限责任公司 1,2,4‑三唑基取代的酮烯醇
US8642774B2 (en) 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
EP2968266B1 (en) 2013-03-15 2019-05-01 Shifa Biomedical Corporation Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds in the treatment and/or prevention of cardiovascular diseases
WO2015175956A1 (en) 2014-05-16 2015-11-19 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
GB201504763D0 (en) * 2015-03-20 2015-05-06 Mironid Ltd Compounds and uses
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
GB201616439D0 (en) 2016-09-28 2016-11-09 Mironid Limited Compounds and uses
WO2019081477A1 (de) * 2017-10-26 2019-05-02 Bayer Cropscience Aktiengesellschaft Substituierte pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe

Also Published As

Publication number Publication date
US11046660B2 (en) 2021-06-29
EP3519403B1 (en) 2021-09-08
WO2018060704A1 (en) 2018-04-05
EP3519403A1 (en) 2019-08-07
JP2019532929A (ja) 2019-11-14
US20200031781A1 (en) 2020-01-30
JP7062643B2 (ja) 2022-05-06

Similar Documents

Publication Publication Date Title
IL273236A (en) Pyrazolopyrimidine compounds and their uses
SG11201706029VA (en) Anti-senescence compounds and uses thereof
IL292488B1 (en) Pyridineamine-pyridone and pyrimidineamine-pyridone compounds
GB201714734D0 (en) New compounds and uses
GB201714740D0 (en) New compounds and uses
ZA201705456B (en) Benzoxaborole compounds and uses thereof
GB201616439D0 (en) Compounds and uses
GB201608779D0 (en) Methods and compounds
GB201504763D0 (en) Compounds and uses
GB201507753D0 (en) New compounds and uses
GB201608776D0 (en) Methods and compounds
IL292482B2 (en) Azaindolylpyridone and diazaindolylpyridone compounds
GB201714736D0 (en) New compounds and uses
IL253459B (en) Isoergoline compounds and their uses
GB201712110D0 (en) New compounds and uses
GB201700404D0 (en) Compounds and composistions
GB201718875D0 (en) Autophagy-inhibiting compounds and uses thereof
GB201614224D0 (en) Compounds and uses thereof
IL265617B (en) 1-phenylpropanone compounds and their use
GB2543375B (en) Compounds and their uses
GB201614874D0 (en) New compounds and uses
GB201720092D0 (en) New Compounds and uses
GB201719327D0 (en) New compounds and uses
GB201719233D0 (en) New compounds and uses
GB201714743D0 (en) New compounds and uses

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)